Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics granted inducement stock options to newly appointed Chief Commercial Officer, Christopher Sarchi, under its 2026 Inducement Plan to encourage his employment. The options comprise 282,240 shares at the closing Nasdaq price on May 8, 2026, and vest over four years. Bicara focuses on developing bifunctional therapies targeting soli…